{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:25:30Z","timestamp":1790767530107,"version":"4.1.0"},"reference-count":193,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Defense Breast Cancer Research Program","award":["W81XWH-21-1-0610"],"award-info":[{"award-number":["W81XWH-21-1-0610"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP190398"],"award-info":[{"award-number":["RP190398"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF 20-145"],"award-info":[{"award-number":["BCRF 20-145"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer immunology is the most rapidly expanding field in cancer research, with the importance of immunity in cancer pathogenesis now well accepted including in the endocrine-related cancers. The immune system plays an essential role in the development of ductal and luminal epithelial differentiation in the mammary gland. Originally identified as evolutionarily conserved antipathogen cytokines, interferons (IFNs) have shown important immune-modulatory and antineoplastic properties when administered to patients with various types of cancer, including breast cancer. Recent studies have drawn attention to the role of tumor- and stromal-infiltrating lymphocytes in dictating therapy response and outcome of breast cancer patients, which, however, is highly dependent on the breast cancer subtype. The emerging role of tumor cell\u2013inherent IFN signaling in the subtype-defined tumor microenvironment could influence therapy response with protumor activities in breast cancer. Here we review evidence with new insights into tumor cell\u2013intrinsic and tumor microenvironment\u2013derived IFN signaling, and the crosstalk of IFN signaling with key signaling pathways in estrogen receptor\u2013positive (ER+) breast cancer. We also discuss clinical implications and opportunities exploiting IFN signaling to treat advanced ER+ breast cancer.<\/jats:p>","DOI":"10.1210\/endocr\/bqab235","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T07:13:25Z","timestamp":1637219605000},"source":"Crossref","is-referenced-by-count":28,"title":["Interferon Signaling in Estrogen Receptor\u2013positive Breast Cancer: A Revitalized Topic"],"prefix":"10.1210","volume":"163","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0005-6496","authenticated-orcid":false,"given":"Xiaoyong","family":"Fu","sequence":"first","affiliation":[{"name":"Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA"},{"name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA"},{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"De Angelis","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Schiff","sequence":"additional","affiliation":[{"name":"Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas 77030, USA"},{"name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA"},{"name":"Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA"},{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"issue":"927","key":"2021120512255719000_CIT0001","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci."},{"issue":"3681","key":"2021120512255719000_CIT0002","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1126\/science.149.3681.310","article-title":"Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin","volume":"149","author":"Wheelock","year":"1965","journal-title":"Science."},{"issue":"1","key":"2021120512255719000_CIT0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol."},{"issue":"2","key":"2021120512255719000_CIT0004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1099\/0022-1317-16-2-251","article-title":"Some properties of virus and immune-induced human lymphocyte interferons","volume":"16","author":"Falcoff","year":"1972","journal-title":"J Gen Virol."},{"issue":"6","key":"2021120512255719000_CIT0005","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.4049\/jimmunol.111.6.1914","article-title":"Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity","volume":"111","author":"Youngner","year":"1973","journal-title":"J Immunol."},{"issue":"8","key":"2021120512255719000_CIT0006","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1158\/0008-5472.CAN-05-3653","article-title":"Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma","volume":"66","author":"Lasfar","year":"2006","journal-title":"Cancer Res."},{"issue":"12","key":"2021120512255719000_CIT0007","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.4049\/jimmunol.176.12.7686","article-title":"Antitumor activity of IFN-lambda in murine tumor models","volume":"176","author":"Sato","year":"2006","journal-title":"J Immunol."},{"issue":"3","key":"2021120512255719000_CIT0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"11","key":"2021120512255719000_CIT0009","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol."},{"issue":"4","key":"2021120512255719000_CIT0010","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00996140","article-title":"Interferons: anti-neoplastic drugs?","volume":"35","author":"Strander","year":"1977","journal-title":"Blut."},{"issue":"6244","key":"2021120512255719000_CIT0011","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/bmj.281.6244.855","article-title":"Does interferon cure cancer?","volume":"281","author":"Sikora","year":"1980","journal-title":"Br Med J."},{"issue":"26","key":"2021120512255719000_CIT0012","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1056\/NEJM197812282992608","article-title":"Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin\u2019s lymphoma","volume":"299","author":"Merigan","year":"1978","journal-title":"N Engl J Med."},{"issue":"1","key":"2021120512255719000_CIT0013","first-page":"47","article-title":"Phase I study of human leukocyte interferon in patients with advanced cancer","volume":"2","author":"Horning","year":"1983","journal-title":"J Biol Response Mod."},{"issue":"12","key":"2021120512255719000_CIT0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov."},{"issue":"3","key":"2021120512255719000_CIT0015","first-page":"869","article-title":"Combination of beta-interferon and tamoxifen as a new way to overcome clinical resistance to tamoxifen in advanced breast cancer","volume":"12","author":"Buzzi","year":"1992","journal-title":"Anticancer Res."},{"issue":"10","key":"2021120512255719000_CIT0016","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/1097-0142(19871115)60:10<2419::AID-CNCR2820601011>3.0.CO;2-S","article-title":"Effect of natural beta-interferon on cell proliferation and steroid receptor level in human breast cancer cells","volume":"60","author":"Sica","year":"1987","journal-title":"Cancer."},{"issue":"3","key":"2021120512255719000_CIT0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/0959-8049(93)90378-S","article-title":"Steroid receptor enhancement by natural interferon-beta in advanced breast cancer","volume":"29A","author":"Sica","year":"1993","journal-title":"Eur J Cancer."},{"issue":"1","key":"2021120512255719000_CIT0018","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF00199838","article-title":"Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy","volume":"24","author":"Tentori","year":"1987","journal-title":"Cancer Immunol Immunother."},{"issue":"3","key":"2021120512255719000_CIT0019","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/med.20143","article-title":"Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor cell biology","volume":"29","author":"Nicolini","year":"2009","journal-title":"Med Res Rev."},{"issue":"6","key":"2021120512255719000_CIT0020","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell."},{"issue":"2","key":"2021120512255719000_CIT0021","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2016.03.031","article-title":"Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling","volume":"165","author":"Minn","year":"2016","journal-title":"Cell."},{"issue":"7","key":"2021120512255719000_CIT0022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1158\/2326-6066.CIR-17-0080","article-title":"Antitumor effects of epidrug\/IFN\u03b1 combination driven by modulated gene signatures in both colorectal cancer and dendritic cells","volume":"5","author":"Fragale","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"6","key":"2021120512255719000_CIT0023","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity."},{"issue":"2","key":"2021120512255719000_CIT0024","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/jnci\/djx137","article-title":"Relevance of spatial heterogeneity of immune infiltration for predicting risk of recurrence after endocrine therapy of ER+ breast cancer","volume":"110","author":"Heindl","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"7668","key":"2021120512255719000_CIT0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature."},{"issue":"2","key":"2021120512255719000_CIT0026","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/2159-8290.CD-17-0915","article-title":"CDK4\/6 inhibition augments antitumor immunity by enhancing T-cell activation","volume":"8","author":"Deng","year":"2018","journal-title":"Cancer Discov."},{"issue":"17","key":"2021120512255719000_CIT0027","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-19-4191","article-title":"Activation of the IFN signaling pathway is associated with resistance to CDK4\/6 inhibitors and immune checkpoint activation in ER-positive breast cancer","volume":"27","author":"De Angelis","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"4 Suppl","key":"2021120512255719000_CIT0028","doi-asserted-by":"crossref","first-page":"Abstract nr PS5-01","DOI":"10.1158\/1538-7445.SABCS20-PS5-01","article-title":"Biomarkers of resistance to palbociclib in ER+ primary breast cancer in the PALLET trial","volume":"81","author":"Schuster","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"2021120512255719000_CIT0029","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41591-018-0302-5","article-title":"Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss","volume":"25","author":"Liu","year":"2019","journal-title":"Nat Med."},{"issue":"2","key":"2021120512255719000_CIT0030","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell."},{"issue":"9","key":"2021120512255719000_CIT0031","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med."},{"issue":"2","key":"2021120512255719000_CIT0032","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"2021120512255719000_CIT0033","doi-asserted-by":"crossref","first-page":"606489","DOI":"10.3389\/fimmu.2020.606489","article-title":"The role of structure in the biology of interferon signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front Immunol."},{"key":"2021120512255719000_CIT0034","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol."},{"issue":"2","key":"2021120512255719000_CIT0035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(92)90106-M","article-title":"A transcription factor with SH2 and SH3 domains is directly activated by an interferon alpha-induced cytoplasmic protein tyrosine kinase(s)","volume":"70","author":"Fu","year":"1992","journal-title":"Cell."},{"issue":"16","key":"2021120512255719000_CIT0036","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1073\/pnas.89.16.7836","article-title":"Proteins of transcription factor ISGF-3: one gene encodes the 91-and 84-kDa ISGF-3 proteins that are activated by interferon alpha","volume":"89","author":"Schindler","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"2021120512255719000_CIT0037","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2021120512255719000_CIT0038","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/jir.1997.17.121","article-title":"GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression","volume":"17","author":"Decker","year":"1997","journal-title":"J Interferon Cytokine Res."},{"key":"2021120512255719000_CIT0039","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1146\/annurev.iy.11.040193.003035","article-title":"The molecular cell biology of interferon-gamma and its receptor","volume":"11","author":"Farrar","year":"1993","journal-title":"Annu Rev Immunol."},{"issue":"5-6","key":"2021120512255719000_CIT0040","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cytogfr.2008.08.004","article-title":"IFNgamma signaling\u2014does it mean JAK-STAT?","volume":"19","author":"Gough","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"2021120512255719000_CIT0041","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev."},{"issue":"1","key":"2021120512255719000_CIT0042","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-\u03bb: immune functions at barrier surfaces and beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity."},{"key":"2021120512255719000_CIT0043","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.micro.55.1.255","article-title":"Viruses and interferons","volume":"55","author":"Sen","year":"2001","journal-title":"Annu Rev Microbiol."},{"issue":"18","key":"2021120512255719000_CIT0044","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1074\/jbc.R116.774562","article-title":"The molecular basis for differential type I interferon signaling","volume":"292","author":"Schreiber","year":"2017","journal-title":"J Biol Chem."},{"issue":"2","key":"2021120512255719000_CIT0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ygeno.2004.03.003","article-title":"Characterization of the type I interferon locus and identification of novel genes","volume":"84","author":"Hardy","year":"2004","journal-title":"Genomics."},{"issue":"7","key":"2021120512255719000_CIT0046","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.cell.2014.11.037","article-title":"Apoptotic caspases prevent the induction of type I interferons by mitochondrial DNA","volume":"159","author":"Rongvaux","year":"2014","journal-title":"Cell."},{"issue":"47","key":"2021120512255719000_CIT0047","doi-asserted-by":"crossref","first-page":"19386","DOI":"10.1073\/pnas.1215006109","article-title":"STING manifests self DNA-dependent inflammatory disease","volume":"109","author":"Ahn","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021120512255719000_CIT0048","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front Immunol."},{"issue":"7","key":"2021120512255719000_CIT0049","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ni1087","article-title":"The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses","volume":"5","author":"Yoneyama","year":"2004","journal-title":"Nat Immunol."},{"issue":"1","key":"2021120512255719000_CIT0050","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.ppat.0040006","article-title":"Distinct TLR- and NLR-mediated transcriptional responses to an intracellular pathogen","volume":"4","author":"Leber","year":"2008","journal-title":"PLoS Pathog."},{"issue":"5","key":"2021120512255719000_CIT0051","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.immuni.2013.05.007","article-title":"Cytosolic sensing of viruses","volume":"38","author":"Goubau","year":"2013","journal-title":"Immunity."},{"issue":"5","key":"2021120512255719000_CIT0052","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.immuni.2013.05.004","article-title":"Immune sensing of DNA","volume":"38","author":"Paludan","year":"2013","journal-title":"Immunity."},{"issue":"7265","key":"2021120512255719000_CIT0053","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature08476","article-title":"STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity","volume":"461","author":"Ishikawa","year":"2009","journal-title":"Nature."},{"issue":"6227","key":"2021120512255719000_CIT0054","doi-asserted-by":"crossref","first-page":"aaa2630","DOI":"10.1126\/science.aaa2630","article-title":"Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation","volume":"347","author":"Liu","year":"2015","journal-title":"Science"},{"issue":"3","key":"2021120512255719000_CIT0055","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","article-title":"Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors","volume":"25","author":"Honda","year":"2006","journal-title":"Immunity."},{"issue":"4","key":"2021120512255719000_CIT0056","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cytogfr.2009.07.005","article-title":"The role of differential expression of human interferon-A genes in antiviral immunity","volume":"20","author":"G\u00e9nin","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"2021120512255719000_CIT0057","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.immuni.2013.02.003","article-title":"Necroptosis: the release of damage-associated molecular patterns and its physiological relevance","volume":"38","author":"Kaczmarek","year":"2013","journal-title":"Immunity."},{"issue":"12","key":"2021120512255719000_CIT0058","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/onc.2016.312","article-title":"Neomorphic mutations create therapeutic challenges in cancer","volume":"36","author":"Takiar","year":"2017","journal-title":"Oncogene."},{"issue":"7689","key":"2021120512255719000_CIT0059","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature."},{"issue":"7676","key":"2021120512255719000_CIT0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature24050","article-title":"Cytoplasmic chromatin triggers inflammation in senescence and cancer","volume":"550","author":"Dou","year":"2017","journal-title":"Nature."},{"issue":"8","key":"2021120512255719000_CIT0061","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/0008-5472.CAN-18-3631","article-title":"Exploiting DNA replication stress for cancer treatment","volume":"79","author":"Ubhi","year":"2019","journal-title":"Cancer Res."},{"issue":"14","key":"2021120512255719000_CIT0062","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-17-2551","article-title":"Interferon-stimulated genes are involved in cross-resistance to radiotherapy in tamoxifen-resistant breast cancer","volume":"24","author":"Post","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"19","key":"2021120512255719000_CIT0063","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancer","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin Cancer Res."},{"issue":"7746","key":"2021120512255719000_CIT0064","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41586-019-0988-7","article-title":"Structure of the IFN\u03b3 receptor complex guides design of biased agonists","volume":"567","author":"Mendoza","year":"2019","journal-title":"Nature."},{"issue":"5","key":"2021120512255719000_CIT0065","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.immuni.2008.08.017","article-title":"Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination","volume":"29","author":"Thieu","year":"2008","journal-title":"Immunity."},{"key":"2021120512255719000_CIT0066","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ncomms2260","article-title":"T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements","volume":"3","author":"Kanhere","year":"2012","journal-title":"Nat Commun."},{"issue":"11","key":"2021120512255719000_CIT0067","doi-asserted-by":"crossref","first-page":"a028423","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5647","key":"2021120512255719000_CIT0068","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.1090148","article-title":"Control of effector CD8+ T cell function by the transcription factor Eomesodermin","volume":"302","author":"Pearce","year":"2003","journal-title":"Science."},{"issue":"6552","key":"2021120512255719000_CIT0069","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature."},{"issue":"3","key":"2021120512255719000_CIT0070","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.4049\/jimmunol.168.3.1146","article-title":"Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1","volume":"168","author":"Nakahira","year":"2002","journal-title":"J Immunol."},{"issue":"6","key":"2021120512255719000_CIT0071","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity."},{"key":"2021120512255719000_CIT0072","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.biochem.67.1.227","article-title":"How cells respond to interferons","volume":"67","author":"Stark","year":"1998","journal-title":"Annu Rev Biochem."},{"issue":"5","key":"2021120512255719000_CIT0073","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1128\/MCB.16.5.2074","article-title":"Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction","volume":"16","author":"Yan","year":"1996","journal-title":"Mol Cell Biol."},{"issue":"12","key":"2021120512255719000_CIT0074","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer."},{"key":"2021120512255719000_CIT0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-\u03b3: teammate or opponent in the tumour microenvironment?","author":"Gocher","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"47","key":"2021120512255719000_CIT0076","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"12","key":"2021120512255719000_CIT0077","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"issue":"6","key":"2021120512255719000_CIT0078","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/PPO.0000000000000007","article-title":"Dendritic cells, inflammation, and breast cancer","volume":"19","author":"Palucka","year":"2013","journal-title":"Cancer J."},{"issue":"22","key":"2021120512255719000_CIT0079","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/1078-0432.CCR-04-0684","article-title":"Dendritic cell infiltration and prognosis of early stage breast cancer","volume":"10","author":"Treilleux","year":"2004","journal-title":"Clin Cancer Res."},{"issue":"20","key":"2021120512255719000_CIT0080","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1158\/0008-5472.CAN-11-3468","article-title":"Impaired IFN-\u03b1 production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression","volume":"72","author":"Sisirak","year":"2012","journal-title":"Cancer Res."},{"issue":"8","key":"2021120512255719000_CIT0081","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol."},{"issue":"2","key":"2021120512255719000_CIT0082","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol."},{"issue":"Pt 2","key":"2021120512255719000_CIT0083","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"24","key":"2021120512255719000_CIT0084","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"2021120512255719000_CIT0085","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"7","key":"2021120512255719000_CIT0086","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat Rev Immunol."},{"issue":"3","key":"2021120512255719000_CIT0087","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nm1554","article-title":"IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy","volume":"13","author":"Berner","year":"2007","journal-title":"Nat Med."},{"issue":"8","key":"2021120512255719000_CIT0088","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/cmi.2017.35","article-title":"B cell regulation in cancer and anti-tumor immunity","volume":"14","author":"Sarvaria","year":"2017","journal-title":"Cell Mol Immunol."},{"issue":"1","key":"2021120512255719000_CIT0089","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1038\/s41467-021-22230-z","article-title":"The survival and function of IL-10-producing regulatory B cells are negatively controlled by SLAMF5","volume":"12","author":"Radomir","year":"2021","journal-title":"Nat Commun."},{"issue":"10","key":"2021120512255719000_CIT0090","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2021120512255719000_CIT0091","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13058-020-01285-8","article-title":"Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial","volume":"22","author":"Skriver","year":"2020","journal-title":"Breast Cancer Res."},{"key":"2021120512255719000_CIT0092","first-page":"289","article-title":"The molecular profile of luminal B breast cancer","volume":"6","author":"Creighton","year":"2012","journal-title":"Biologics."},{"issue":"1","key":"2021120512255719000_CIT0093","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-014-2991-x","article-title":"Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data","volume":"146","author":"Haricharan","year":"2014","journal-title":"Breast Cancer Res Treat."},{"issue":"7","key":"2021120512255719000_CIT0094","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djz213","article-title":"Immune checkpoint profiles in luminal B breast cancer (alliance)","volume":"112","author":"Anurag","year":"2020","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"2021120512255719000_CIT0095","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/nri1733","article-title":"Monocyte and macrophage heterogeneity","volume":"5","author":"Gordon","year":"2005","journal-title":"Nat Rev Immunol."},{"key":"2021120512255719000_CIT0096","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fonc.2020.00188","article-title":"Tumor-associated macrophages: recent insights and therapies","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol."},{"key":"2021120512255719000_CIT0097","doi-asserted-by":"crossref","first-page":"13050","DOI":"10.1038\/ncomms13050","article-title":"Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers","volume":"7","author":"Allaoui","year":"2016","journal-title":"Nat Commun."},{"issue":"3","key":"2021120512255719000_CIT0098","doi-asserted-by":"crossref","first-page":"e58913","DOI":"10.1371\/journal.pone.0058913","article-title":"Direct transformation of lung microenvironment by interferon-\u03b1 treatment counteracts growth of lung metastasis of hepatocellular carcinoma","volume":"8","author":"Zhuang","year":"2013","journal-title":"PLoS One."},{"key":"2021120512255719000_CIT0099","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2018.00049","article-title":"Targeting macrophages in cancer: from bench to bedside","volume":"8","author":"Poh","year":"2018","journal-title":"Front Oncol."},{"issue":"4","key":"2021120512255719000_CIT0100","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10555-018-9768-3","article-title":"Cancer-associated fibroblasts as key regulators of the breast cancer tumor microenvironment","volume":"37","author":"Houthuijzen","year":"2018","journal-title":"Cancer Metastasis Rev."},{"issue":"20","key":"2021120512255719000_CIT0101","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.7150\/jca.28054","article-title":"Activated tumor-infiltrating fibroblasts predict worse prognosis in breast cancer patients","volume":"9","author":"Hu","year":"2018","journal-title":"J Cancer."},{"issue":"24","key":"2021120512255719000_CIT0102","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.7150\/jca.28583","article-title":"Cancer-Associated fibroblasts correlate with tumor-associated macrophages infiltration and lymphatic metastasis in triple negative breast cancer patients","volume":"9","author":"Zhou","year":"2018","journal-title":"J Cancer."},{"issue":"1","key":"2021120512255719000_CIT0103","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12943-019-0960-z","article-title":"Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer","volume":"18","author":"Plava","year":"2019","journal-title":"Mol Cancer."},{"key":"2021120512255719000_CIT0104","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12885-015-1117-0","article-title":"A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer","volume":"15","author":"Hosein","year":"2015","journal-title":"BMC Cancer."},{"issue":"6","key":"2021120512255719000_CIT0105","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41416-020-01226-4","article-title":"Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy","volume":"124","author":"Broad","year":"2021","journal-title":"Br J Cancer."},{"issue":"5","key":"2021120512255719000_CIT0106","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/1878-0261.12905","article-title":"IFN\u03b21 secreted by breast cancer cells undergoing chemotherapy reprograms stromal fibroblasts to support tumour growth after treatment","volume":"15","author":"Maia","year":"2021","journal-title":"Mol Oncol."},{"issue":"1","key":"2021120512255719000_CIT0107","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1038\/s41598-019-39553-z","article-title":"Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1+ TAMs","volume":"9","author":"Gok Yavuz","year":"2019","journal-title":"Sci Rep."},{"issue":"11","key":"2021120512255719000_CIT0108","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","article-title":"Molecular pathways: interferon\/Stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth","volume":"18","author":"Khodarev","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"10","key":"2021120512255719000_CIT0109","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.4049\/jimmunol.1801152","article-title":"Progesterone receptor attenuates STAT1-mediated IFN signaling in breast cancer","volume":"202","author":"Goodman","year":"2019","journal-title":"J Immunol."},{"issue":"1","key":"2021120512255719000_CIT0110","doi-asserted-by":"crossref","first-page":"1758547","DOI":"10.1080\/2162402X.2020.1758547","article-title":"Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer","volume":"9","author":"Walter","year":"2020","journal-title":"Oncoimmunology."},{"issue":"10","key":"2021120512255719000_CIT0111","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1158\/1541-7786.MCR-17-0180","article-title":"Interferon-stimulated genes are transcriptionally repressed by PR in breast cancer","volume":"15","author":"Walter","year":"2017","journal-title":"Mol Cancer Res."},{"issue":"15","key":"2021120512255719000_CIT0112","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-2463","article-title":"Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)","volume":"22","author":"Alfaro","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"43","key":"2021120512255719000_CIT0113","doi-asserted-by":"crossref","first-page":"E6600","DOI":"10.1073\/pnas.1612835113","article-title":"FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer","volume":"113","author":"Fu","year":"2016","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"2021120512255719000_CIT0114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/imr.12614","article-title":"IL-1 and IL-1 regulatory pathways in cancer progression and therapy","volume":"281","author":"Mantovani","year":"2018","journal-title":"Immunol Rev."},{"issue":"5","key":"2021120512255719000_CIT0115","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ccr.2008.10.011","article-title":"Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice","volume":"14","author":"Tu","year":"2008","journal-title":"Cancer Cell."},{"issue":"2","key":"2021120512255719000_CIT0116","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1074\/jbc.M607674200","article-title":"A novel c-Jun-dependent signal transduction pathway necessary for the transcriptional activation of interferon gamma response genes","volume":"282","author":"Gough","year":"2007","journal-title":"J Biol Chem."},{"issue":"3","key":"2021120512255719000_CIT0117","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-12-2731","article-title":"The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition","volume":"19","author":"Jiang","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"11","key":"2021120512255719000_CIT0118","doi-asserted-by":"crossref","first-page":"e0166626","DOI":"10.1371\/journal.pone.0166626","article-title":"RAS-mitogen-activated protein kinase signal is required for enhanced PD-L1 expression in human lung cancers","volume":"11","author":"Sumimoto","year":"2016","journal-title":"PLoS One."},{"issue":"3","key":"2021120512255719000_CIT0119","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bjc.1987.49","article-title":"Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen","volume":"55","author":"van den Berg","year":"1987","journal-title":"Br J Cancer."},{"issue":"6B","key":"2021120512255719000_CIT0120","first-page":"2061","article-title":"Effect of natural beta-interferon on estrogen receptor mRNA of breast cancer cells","volume":"12","author":"Sica","year":"1992","journal-title":"Anticancer Res."},{"issue":"2","key":"2021120512255719000_CIT0121","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bjc.1993.339","article-title":"Interferon plus tamoxifen treatment for advanced breast cancer: in vivo biologic effects of two growth modulators","volume":"68","author":"Seymour","year":"1993","journal-title":"Br J Cancer."},{"issue":"2","key":"2021120512255719000_CIT0122","first-page":"537","article-title":"In vivo effect induced by interferon beta on steroid receptor status, cell kinetics and DNA ploidy in operable breast cancer patients","volume":"15","author":"Di Martino","year":"1995","journal-title":"Anticancer Res."},{"issue":"3","key":"2021120512255719000_CIT0123","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.yhbeh.2012.04.011","article-title":"Estrogen receptors regulate an inflammatory pathway of dendritic cell differentiation: mechanisms and implications for immunity","volume":"62","author":"Kovats","year":"2012","journal-title":"Horm Behav."},{"issue":"2","key":"2021120512255719000_CIT0124","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cellimm.2015.01.018","article-title":"Estrogen receptors regulate innate immune cells and signaling pathways","volume":"294","author":"Kovats","year":"2015","journal-title":"Cell Immunol."},{"issue":"3-4","key":"2021120512255719000_CIT0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3109\/00207459008999730","article-title":"The influence of beta-estradiol and progesterone on interferon gamma production in vitro","volume":"51","author":"Grasso","year":"1990","journal-title":"Int J Neurosci."},{"issue":"12","key":"2021120512255719000_CIT0126","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.4049\/jimmunol.146.12.4362","article-title":"Estrogen regulates the IFN-gamma promoter","volume":"146","author":"Fox","year":"1991","journal-title":"J Immunol."},{"issue":"3","key":"2021120512255719000_CIT0127","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/intimm\/dxl151","article-title":"Treg suppressive activity involves estrogen-dependent expression of programmed death-1 (PD-1)","volume":"19","author":"Polanczyk","year":"2007","journal-title":"Int Immunol."},{"issue":"2","key":"2021120512255719000_CIT0128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/jcp.21221","article-title":"Induction of regulatory T cells by physiological level estrogen","volume":"214","author":"Tai","year":"2008","journal-title":"J Cell Physiol."},{"issue":"1","key":"2021120512255719000_CIT0129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-16-0502","article-title":"Tumor cell-independent estrogen signaling drives disease progression through mobilization of myeloid-derived suppressor cells","volume":"7","author":"Svoronos","year":"2017","journal-title":"Cancer Discov."},{"key":"2021120512255719000_CIT0130","article-title":"Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells","author":"H\u00fchn","year":"15, 2021","journal-title":"Mol Oncol"},{"issue":"1","key":"2021120512255719000_CIT0131","doi-asserted-by":"crossref","first-page":"e87377","DOI":"10.1371\/journal.pone.0087377","article-title":"Activation of ER\u03b1 signaling differentially modulates IFN-\u03b3 induced HLA-class II expression in breast cancer cells","volume":"9","author":"Mostafa","year":"2014","journal-title":"PLoS One."},{"issue":"3","key":"2021120512255719000_CIT0132","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1023\/A:1006132427948","article-title":"Steroid hormone receptors in breast cancer management","volume":"51","author":"Osborne","year":"1998","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"2021120512255719000_CIT0133","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1073\/pnas.67.2.501","article-title":"Progesterone \u201creceptors\u201d in the cytoplasm and nucleus of chick oviduct target tissue","volume":"67","author":"O\u2019Malley","year":"1970","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"7560","key":"2021120512255719000_CIT0134","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature."},{"issue":"1","key":"2021120512255719000_CIT0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nrc.2016.116","article-title":"Deciphering the divergent roles of progestogens in breast cancer","volume":"17","author":"Carroll","year":"2017","journal-title":"Nat Rev Cancer."},{"issue":"2","key":"2021120512255719000_CIT0136","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.imlet.2009.07.003","article-title":"Progesterone inhibits Toll-like receptor 4-mediated innate immune response in macrophages by suppressing NF-kappaB activation and enhancing SOCS1 expression","volume":"125","author":"Su","year":"2009","journal-title":"Immunol Lett."},{"issue":"11","key":"2021120512255719000_CIT0137","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1210\/me.2006-0112","article-title":"Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression","volume":"20","author":"Hardy","year":"2006","journal-title":"Mol Endocrinol."},{"issue":"8","key":"2021120512255719000_CIT0138","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.0901155","article-title":"Differential modulation of TLR3- and TLR4-mediated dendritic cell maturation and function by progesterone","volume":"185","author":"Jones","year":"2010","journal-title":"J Immunol."},{"issue":"2","key":"2021120512255719000_CIT0139","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1097-2765(02)00459-8","article-title":"Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4","volume":"9","author":"Cirillo","year":"2002","journal-title":"Mol Cell."},{"issue":"1","key":"2021120512255719000_CIT0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.molcel.2016.03.001","article-title":"The pioneer transcription factor FoxA maintains an accessible nucleosome configuration at enhancers for tissue-specific gene activation","volume":"62","author":"Iwafuchi-Doi","year":"2016","journal-title":"Mol Cell."},{"issue":"6","key":"2021120512255719000_CIT0141","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","article-title":"FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell."},{"issue":"1","key":"2021120512255719000_CIT0142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cell.2005.05.008","article-title":"Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1","volume":"122","author":"Carroll","year":"2005","journal-title":"Cell."},{"issue":"1","key":"2021120512255719000_CIT0143","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.730","article-title":"FOXA1 is a key determinant of estrogen receptor function and endocrine response","volume":"43","author":"Hurtado","year":"2011","journal-title":"Nat Genet."},{"issue":"7381","key":"2021120512255719000_CIT0144","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature10730","article-title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","volume":"481","author":"Ross-Innes","year":"2012","journal-title":"Nature."},{"issue":"52","key":"2021120512255719000_CIT0145","doi-asserted-by":"crossref","first-page":"26823","DOI":"10.1073\/pnas.1911584116","article-title":"FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer","volume":"116","author":"Fu","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"2021120512255719000_CIT0146","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell."},{"issue":"7661","key":"2021120512255719000_CIT0147","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature22992","article-title":"Recurrent and functional regulatory mutations in breast cancer","volume":"547","author":"Rheinbay","year":"2017","journal-title":"Nature."},{"issue":"4","key":"2021120512255719000_CIT0148","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ccell.2020.08.003","article-title":"FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer","volume":"38","author":"Arruabarrena-Aristorena","year":"2020","journal-title":"Cancer Cell."},{"issue":"14","key":"2021120512255719000_CIT0149","doi-asserted-by":"crossref","first-page":"e147025","DOI":"10.1172\/JCI147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J Clin Invest"},{"issue":"6","key":"2021120512255719000_CIT0150","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1245\/s10434-014-4313-2","article-title":"FOXA1 expression significantly predict response to chemotherapy in estrogen receptor-positive breast cancer patients","volume":"22","author":"Xu","year":"2015","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"2021120512255719000_CIT0151","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/bjc.2014.595","article-title":"Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases","volume":"112","author":"Horimoto","year":"2015","journal-title":"Br J Cancer."},{"issue":"5","key":"2021120512255719000_CIT0152","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med."},{"issue":"5","key":"2021120512255719000_CIT0153","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med."},{"issue":"3","key":"2021120512255719000_CIT0154","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nm.3485","article-title":"FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS","volume":"20","author":"Liu","year":"2014","journal-title":"Nat Med."},{"key":"2021120512255719000_CIT0155","doi-asserted-by":"crossref","first-page":"14709","DOI":"10.1038\/ncomms14709","article-title":"Neuronal IFN-beta-induced PI3K\/Akt-FoxA1 signalling is essential for generation of FoxA1+Treg cells","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun."},{"issue":"1","key":"2021120512255719000_CIT0156","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bbrc.2019.04.152","article-title":"FOXA1+ regulatory T cells: a novel T cell subset that suppresses antitumor immunity in lung cancer","volume":"514","author":"Liang","year":"2019","journal-title":"Biochem Biophys Res Commun."},{"issue":"2","key":"2021120512255719000_CIT0157","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3204","article-title":"The diverse and complex roles of NF-\u03baB subunits in cancer","volume":"12","author":"Perkins","year":"2012","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"2021120512255719000_CIT0158","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri.2017.142","article-title":"NF-\u03baB, inflammation, immunity and cancer: coming of age","volume":"18","author":"Taniguchi","year":"2018","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"2021120512255719000_CIT0159","doi-asserted-by":"crossref","first-page":"R369","DOI":"10.1530\/ERC-19-0087","article-title":"The NF-KB pathway and endocrine therapy resistance in breast cancer","volume":"26","author":"Khongthong","year":"2019","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2021120512255719000_CIT0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/bcr3196","article-title":"The interaction between ER and NF\u03baB in resistance to endocrine therapy","volume":"14","author":"Sas","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"6","key":"2021120512255719000_CIT0161","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ni1465","article-title":"The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways","volume":"8","author":"Zhao","year":"2007","journal-title":"Nat Immunol."},{"key":"2021120512255719000_CIT0162","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12864-015-1511-7","article-title":"NF-\u03baB and IRF pathways: cross-regulation on target genes promoter level","volume":"16","author":"Iwanaszko","year":"2015","journal-title":"BMC Genomics."},{"issue":"6","key":"2021120512255719000_CIT0163","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1128\/JVI.02213-10","article-title":"Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses","volume":"85","author":"Basagoudanavar","year":"2011","journal-title":"J Virol."},{"key":"2021120512255719000_CIT0164","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3389\/fimmu.2019.01425","article-title":"An NF\u03baB activity calculator to delineate signaling crosstalk: type I and II interferons enhance NF\u03baB via distinct mechanisms","volume":"10","author":"Mitchell","year":"2019","journal-title":"Front Immunol."},{"issue":"6","key":"2021120512255719000_CIT0165","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1096\/fj.09-138305","article-title":"BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells","volume":"24","author":"Nehra","year":"2010","journal-title":"FASEB J."},{"issue":"5","key":"2021120512255719000_CIT0166","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/1535-7163.MCT-09-1169","article-title":"IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis","volume":"9","author":"Ning","year":"2010","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"2021120512255719000_CIT0167","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.stemcr.2020.06.020","article-title":"Increased expression of interleukin-1 receptor characterizes anti-estrogen-resistant ALDH+ breast cancer stem cells","volume":"15","author":"Sarmiento-Castro","year":"2020","journal-title":"Stem Cell Reports."},{"issue":"1","key":"2021120512255719000_CIT0168","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-019-12807-0","article-title":"Microenvironmental IL1\u03b2 promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling","volume":"10","author":"Eyre","year":"2019","journal-title":"Nat Commun."},{"issue":"2-3","key":"2021120512255719000_CIT0169","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.antiviral.2006.03.006","article-title":"Anti-inflammatory properties of type I interferons","volume":"71","author":"Billiau","year":"2006","journal-title":"Antiviral Res."},{"issue":"1","key":"2021120512255719000_CIT0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/cmi.2016.25","article-title":"Clash of the cytokine titans: counter-regulation of interleukin-1 and type I interferon-mediated inflammatory responses","volume":"14","author":"Mayer-Barber","year":"2017","journal-title":"Cell Mol Immunol."},{"key":"2021120512255719000_CIT0171","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.0105-2896.2005.00332.x","article-title":"Fos\/AP-1 proteins in bone and the immune system","volume":"208","author":"Wagner","year":"2005","journal-title":"Immunol Rev."},{"issue":"2","key":"2021120512255719000_CIT0172","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/jlb.63.2.139","article-title":"Transcriptional regulation in the immune system: all roads lead to AP-1","volume":"63","author":"Foletta","year":"1998","journal-title":"J Leukoc Biol."},{"issue":"7","key":"2021120512255719000_CIT0173","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/cancers11071037","article-title":"AP-1 transcription factors as regulators of immune responses in cancer","volume":"11","author":"Atsaves","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"2021120512255719000_CIT0174","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrc1209","article-title":"AP-1: a double-edged sword in tumorigenesis","volume":"3","author":"Eferl","year":"2003","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"2021120512255719000_CIT0175","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat Rev Immunol."},{"key":"2021120512255719000_CIT0176","doi-asserted-by":"crossref","first-page":"1758835919830826","DOI":"10.1177\/1758835919830826","article-title":"Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials","volume":"11","author":"Pelster","year":"2019","journal-title":"Ther Adv Med Oncol."},{"issue":"4 Suppl","key":"2021120512255719000_CIT0177","doi-asserted-by":"crossref","first-page":"Abstract nr PD8-03","DOI":"10.1158\/1538-7445.SABCS20-PD8-03","article-title":"A FOXA1\/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer","volume":"81","author":"Fu","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"2021120512255719000_CIT0178","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s43018-020-00135-y","article-title":"CDK4\/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity","volume":"2","author":"Watt","year":"2021","journal-title":"Nat Cancer."},{"key":"2021120512255719000_CIT0179","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41523-018-0060-z","article-title":"Phase II study of ruxolitinib, a selective JAK1\/2 inhibitor, in patients with metastatic triple-negative breast cancer","volume":"4","author":"Stover","year":"2018","journal-title":"NPJ Breast Cancer."},{"issue":"3","key":"2021120512255719000_CIT0180","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ccell.2020.06.007","article-title":"IL6\/STAT3 signaling hijacks estrogen receptor \u03b1 enhancers to drive breast cancer metastasis","volume":"38","author":"Siersb\u00e6k","year":"2020","journal-title":"Cancer Cell."},{"issue":"42","key":"2021120512255719000_CIT0181","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1038\/s41388-020-01454-1","article-title":"Combined inhibition of JAK2-STAT3 and SMO-GLI1\/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis","volume":"39","author":"Doheny","year":"2020","journal-title":"Oncogene."},{"issue":"4","key":"2021120512255719000_CIT0182","first-page":"5581","article-title":"Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells","volume":"17","author":"Lim","year":"2018","journal-title":"Mol Med Rep."},{"issue":"4","key":"2021120512255719000_CIT0183","first-page":"3981","article-title":"Inhibition of tumor growth and angiogenesis of tamoxifen-resistant breast cancer cells by ruxolitinib, a selective JAK2 inhibitor","volume":"17","author":"Kim","year":"2019","journal-title":"Oncol Lett."},{"key":"2021120512255719000_CIT0184","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/978-981-10-6020-5_18","article-title":"Immune checkpoint blockade in breast cancer therapy","volume":"1026","author":"Bu","year":"2017","journal-title":"Adv Exp Med Biol."},{"key":"2021120512255719000_CIT0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2020.06.016","article-title":"Immune checkpoint inhibitors: key trials and an emerging role in breast cancer","author":"Gaynor","year":"2020","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2021120512255719000_CIT0186","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.humpath.2015.09.003","article-title":"PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas","volume":"47","author":"Cimino-Mathews","year":"2016","journal-title":"Hum Pathol."},{"issue":"11","key":"2021120512255719000_CIT0187","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-16-2569","article-title":"Immunotherapy for breast cancer: what are we missing?","volume":"23","author":"Vonderheide","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2021120512255719000_CIT0188","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.cyto.2015.06.012","article-title":"Interplay between inflammatory and estrogen signaling in breast cancer","volume":"76","author":"Nagari","year":"2015","journal-title":"Cytokine."},{"issue":"2","key":"2021120512255719000_CIT0189","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/ijms19020611","article-title":"The role of the estrogen pathway in the tumor microenvironment","volume":"19","author":"Rothenberger","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2021120512255719000_CIT0190","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/2326-6066.CIR-17-0150","article-title":"Neoadjuvant interferons: critical for effective PD-1-based immunotherapy in TNBC","volume":"5","author":"Brockwell","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"18","key":"2021120512255719000_CIT0191","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1158\/0008-5472.CAN-08-1404","article-title":"Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts","volume":"68","author":"Creighton","year":"2008","journal-title":"Cancer Res."},{"issue":"9","key":"2021120512255719000_CIT0192","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","article-title":"Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer","volume":"10","author":"Deblois","year":"2020","journal-title":"Cancer Discov."},{"issue":"2","key":"2021120512255719000_CIT0193","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.celrep.2019.08.105","article-title":"Reduction of global H3K27me3 enhances HER2\/ErbB2 targeted therapy","volume":"29","author":"Hirukawa","year":"2019","journal-title":"Cell Rep."}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqab235\/41161031\/bqab235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/163\/1\/bqab235\/41532780\/bqab235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/163\/1\/bqab235\/41532780\/bqab235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T19:06:49Z","timestamp":1673809609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqab235\/6429717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":193,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqab235","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,11,16]]},"article-number":"bqab235"}}